ArticleNPJ digital medicine2026
Challenges in applying the EU AI act research exemptions to contemporary AI research.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond benchmark accuracy: Toward trustworthy, open, and agentic clinical artificial intelligence.Pediatric investigation · 2026Article
- Assessing the risk of bias of clinical trials with large language models and ROBUST-RCT: a feasibility study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EU Artificial Intelligence Act (AI Act) is the world's first comprehensive, cross-sectoral legal framework dedicated specifically to AI. It introduces a structured regulatory approach to ensure that AI systems are safe, transparent, and trustworthy. To foster innovation, it includes research exemptions that place certain AI systems - those under development or used solely for scientific research - outside of its scope and obligations. However, this paper argues that these exemptions rely on distinctions that may not fully capture the realities of contemporary AI research. These include the unclear divide between research and commercial activities, and between lab-based development and real-world testing. Through legal analysis and practical scenarios, we demonstrate how the blurred boundaries between academic and commercial interests, as well as between controlled research and real-world use, create regulatory uncertainty and open the door to potential misuse. The paper highlights the risks stemming from vague definitions and the lack of harmonized guidance. It ultimately calls for clearer guidance, stronger safeguards, and more realistic frameworks that reflect the complexities of modern AI research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.